The European Medicines Agency (EMA) has recommended the marketing authorisation of Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older with a stage 2 diagnosis.[1][3] Teplizumab is an antibody that slows the autoimmune attack on the insulin-producing cells of the pancreas, delaying the point at which patients become dependent on daily insulin injections.1][2] The drug is administered as a 14-day series of once-daily intravenous infusions.[1][3] In the TN-10 clinical trial, teplizumab approximately doubled the median time to development of stage 3 diabetes - from about 25 months in the placebo group to 50 months in the drug group.[1][2] Type 1 diabetes developed in 45% of patients treated with teplizumab compared to 72% of patients in the placebo group.[2][5] Teplizumab is a first-in-class treatment with the potential to realistically delay the onset of type 1 diabetes and improve the quality of life of patients, especially children, who may thus avoid earlier initiation of insulin therapy[7].